X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES WOCKHARDT SUVEN LIFESCIENCES/
WOCKHARDT
 
P/E (TTM) x 21.2 -18.3 - View Chart
P/BV x 4.1 1.3 323.7% View Chart
Dividend Yield % 0.6 0.0 18,285.3%  

Financials

 SUVEN LIFESCIENCES   WOCKHARDT
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
WOCKHARDT
Mar-18
SUVEN LIFESCIENCES/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs2511,012 24.8%   
Low Rs155532 29.2%   
Sales per share (Unadj.) Rs49.1355.9 13.8%  
Earnings per share (Unadj.) Rs9.7-60.3 -16.1%  
Cash flow per share (Unadj.) Rs11.4-46.8 -24.4%  
Dividends per share (Unadj.) Rs1.500.01 15,000.0%  
Dividend yield (eoy) %0.70 57,054.0%  
Book value per share (Unadj.) Rs60.3257.8 23.4%  
Shares outstanding (eoy) m127.28110.63 115.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.12.2 190.5%   
Avg P/E ratio x20.9-12.8 -163.1%  
P/CF ratio (eoy) x17.8-16.5 -107.9%  
Price / Book Value ratio x3.43.0 112.4%  
Dividend payout %15.40 -93,044.3%   
Avg Mkt Cap Rs m25,82585,379 30.2%   
No. of employees `0001.16.3 17.1%   
Total wages/salary Rs m6139,371 6.5%   
Avg. sales/employee Rs Th5,832.66,295.0 92.7%   
Avg. wages/employee Rs Th571.51,498.3 38.1%   
Avg. net profit/employee Rs Th1,153.8-1,066.3 -108.2%   
INCOME DATA
Net Sales Rs m6,25339,369 15.9%  
Other income Rs m2331,202 19.4%   
Total revenues Rs m6,48540,571 16.0%   
Gross profit Rs m1,98218 10,829.5%  
Depreciation Rs m2131,495 14.3%   
Interest Rs m462,555 1.8%   
Profit before tax Rs m1,955-2,830 -69.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m718257 279.5%   
Profit after tax Rs m1,237-6,669 -18.5%  
Gross profit margin %31.70 68,187.1%  
Effective tax rate %36.7-9.1 -404.5%   
Net profit margin %19.8-16.9 -116.8%  
BALANCE SHEET DATA
Current assets Rs m5,62233,796 16.6%   
Current liabilities Rs m1,16826,917 4.3%   
Net working cap to sales %71.217.5 407.7%  
Current ratio x4.81.3 383.5%  
Inventory Days Days8179 102.6%  
Debtors Days Days3689 40.3%  
Net fixed assets Rs m3,32539,664 8.4%   
Share capital Rs m127553 23.0%   
"Free" reserves Rs m7,54727,968 27.0%   
Net worth Rs m7,67428,522 26.9%   
Long term debt Rs m1421,731 0.1%   
Total assets Rs m9,13581,620 11.2%  
Interest coverage x43.2-0.1 -40,203.9%   
Debt to equity ratio x00.8 0.2%  
Sales to assets ratio x0.70.5 141.9%   
Return on assets %14.0-5.0 -278.7%  
Return on equity %16.1-23.4 -68.9%  
Return on capital %26.0-7.7 -339.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,0669,807 51.7%   
Fx outflow Rs m2,0011,789 111.9%   
Net fx Rs m3,0658,019 38.2%   
CASH FLOW
From Operations Rs m699684 102.2%  
From Investments Rs m-66,302 -0.1%  
From Financial Activity Rs m-577-7,695 7.5%  
Net Cashflow Rs m116-664 -17.5%  

Share Holding

Indian Promoters % 63.4 74.5 85.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 2.3 -  
FIIs % 0.0 7.7 -  
ADR/GDR % 0.0 0.1 -  
Free float % 36.5 15.4 237.0%  
Shareholders   37,287 67,757 55.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   DISHMAN PHARMA  ELDER PHARMA  AUROBINDO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Lower; IT Stocks Under Pressure(09:30 am)

Asian share markets edged near this year's peak while benchmark US treasury yields, and the dollar dropped after the Federal Reserve signaled possible interest rate cuts later this year.

Related Views on News

WOCKHARDT Plunges by 7%; BSE HEALTHCARE Index Down 0.4% (Market Updates)

Jun 20, 2019 | Updated on Jun 20, 2019

WOCKHARDT share price has plunged by 7% and its current market price is Rs 340. The BSE HEALTHCARE is down by 0.4%. The top gainers in the BSE HEALTHCARE Index are ERIS LIFESCIENCES LIMITED (up 2.6%) and APOLLO HOSPITALS (up 2.1%). The top losers is WOCKHARDT (down 6.9%)..

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jun 20, 2019 10:17 AM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS